Luminex Corporation (LMNX) Just Reaches 52-Week High?

May 17, 2018 - By Melody Miller

Luminex Corporation (NASDAQ:LMNX) Logo

The stock of Luminex Corporation (NASDAQ:LMNX) hit a new 52-week high and has $28.66 target or 9.00 % above today’s $26.29 share price. The 9 months bullish chart indicates low risk for the $1.17B company. The 1-year high was reported on May, 17 by Barchart.com. If the $28.66 price target is reached, the company will be worth $105.21M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.11% or $0.03 during the last trading session, reaching $26.29. About 113,745 shares traded. Luminex Corporation (NASDAQ:LMNX) has risen 15.14% since May 17, 2017 and is uptrending. It has outperformed by 3.59% the S&P500.

Analysts await Luminex Corporation (NASDAQ:LMNX) to report earnings on August, 6. They expect $0.20 EPS, 0.00 % or $0.00 from last year’s $0.2 per share. LMNX’s profit will be $8.89M for 32.86 P/E if the $0.20 EPS becomes a reality. After $0.25 actual EPS reported by Luminex Corporation for the previous quarter, Wall Street now forecasts -20.00 % negative EPS growth.

Luminex Corporation (NASDAQ:LMNX) Ratings Coverage

Among 2 analysts covering Luminex (NASDAQ:LMNX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Luminex had 3 analyst reports since January 5, 2018 according to SRatingsIntel. Deutsche Bank upgraded Luminex Corporation (NASDAQ:LMNX) rating on Monday, May 7. Deutsche Bank has “Hold” rating and $2200 target.

More recent Luminex Corporation (NASDAQ:LMNX) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For May 7, 2018” on May 07, 2018. Also Seekingalpha.com published the news titled: “Luminex Corporation’s (LMNX) CEO Homi Shamir on Q1 2018 Results – Earnings Call Transcript” on May 08, 2018. Globenewswire.com‘s news article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Bottomline Technologies, SkyWest, Pacific …” with publication date: April 27, 2018 was also an interesting one.

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and life sciences industries worldwide. The company has market cap of $1.17 billion. The company's products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; Verigene system, an automated multiplex-capable system; and ARIES system, a sample to answer real-time PCR platform. It has a 39.3 P/E ratio. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; ARIES cassettes that are self-contained assay consumables; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; respiratory viral family of products to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel assays to identify the pathogens causing infectious gastroenteritis.

Luminex Corporation (NASDAQ:LMNX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.